What we know now: microbiome diversity is linked to health, but not yet a clinical target
The gut microbiome—the trillions of bacteria living in your intestines—is now understood to play a key role in chronic diseases like heart disease, depression, liver disease, and obesity [1]. Higher diversity (more different types of bacteria) is generally associated with better health. For example, a large U.S. national survey (NHANES) found that people who ate more live microbes (from fermented foods or probiotics) had higher levels of fat-soluble vitamins and better cardiovascular health scores [1]. Another study showed that in people with COPD, higher dietary live microbe intake was linked to lower rates of depression [1]. These associations are consistent across many studies, but they are not yet strong enough to form the basis of clinical guidelines.
The problem is that 'healthy microbiome' has no standard definition. A 2024 review in the journal Gut points out that the term 'dysbiosis' (imbalance) is used too loosely, and that individual factors like diet, lifestyle, age, and even genetics make it hard to say what a 'normal' microbiome looks like for any given person [6]. Another review highlights that most microbiome research has been done on people of European descent, so we don't yet know what a healthy microbiome looks like in diverse global populations [4]. Without that baseline, doctors cannot yet use microbiome diversity as a diagnostic or treatment target.
What was previously believed: that we could quickly turn microbiome science into clinical tools
Early hype suggested that measuring your gut bacteria would soon lead to personalized diets, probiotics, or even fecal transplants for common conditions. But the reality is more cautious. A 2025 protocol for a systematic review of probiotics for constipation notes that while probiotics are promising, the evidence from randomized controlled trials is still being gathered—the review itself is not yet complete [2]. Similarly, a 2024 study on a traditional Chinese medicine (Huaier polysaccharides) for liver cancer showed that it works partly by changing the gut microbiome, but this was in mice and cell cultures, not yet in human trials [3]. So while the mechanism is plausible, human clinical evidence is still in early stages.
Another shift is the recognition that microbiome changes are often correlated with disease, not necessarily causing it. For example, a 2021 study on preterm infants found that early disruptions to the gut microbiome are linked to later immune and metabolic diseases, but the authors caution that the exact mechanisms are not fully understood [7]. This means we cannot yet say 'fix the microbiome, fix the disease' with confidence. The field is moving from correlation to causation, but that transition is not complete.
Where the evidence stands now: promising but not prescriptive
The most actionable evidence today is about diet and probiotics. A 2026 editorial summarizing multiple studies concludes that dietary intake of live microbes and probiotics can improve blood lipids, reduce inflammation, and support liver health [1]. For example, a systematic review of eight randomized controlled trials found that probiotics increased 'good' HDL cholesterol and antioxidants while lowering 'bad' LDL cholesterol and inflammatory markers like C-reactive protein [1]. These are measurable health benefits, but they are not specifically tied to microbiome diversity—they could work through other mechanisms.
A 2025 clinical trial on infected eczema used whole-genome sequencing to personalize antibiotic treatment based on each patient's skin and gut microbiome. The group that got personalized treatment showed faster recovery of a healthy gut microbiome compared to standard care [5]. This is one of the first studies to show that microbiome-guided therapy can improve outcomes in a real clinical setting. However, it was a small trial (60 patients) and focused on a specific condition, so it does not yet support broad clinical recommendations for microbiome diversity.
In summary, the evidence is strong enough to say that a diverse gut microbiome is generally good for health, and that diet and probiotics can help. But it is not yet strong enough for doctors to prescribe specific microbiome targets or tests for the general population. The field is actively working on defining what a 'healthy' microbiome looks like across different populations [4][6], and once that is established, clinical recommendations will follow.
About These Sources
This answer is built on 7 peer-reviewed studies — published from 2021 to 2026, 6 from 2024 or later, 5 in Q1 journals, collectively cited 359 times — selected as the most relevant from 7 studies that passed quality screening, drawn from 62 papers retrieved from a database of over 500 million.
Sources used in this answer
Editorial: Xenobiotics, gut microbiota, and chronic disease
A 2026 editorial summarizing multiple studies (including NHANES surveys and systematic reviews) shows that dietary live microbe intake and probiotics are associated with better cardiovascular health, higher fat-soluble vitamins, lower inflammation, and reduced depression in COPD patients, but notes the field must shift from correlation to mechanism and personalization.
Probiotics interventions modulating gut microbiota composition in individuals with intestinal constipation: Protocol of a systemic review and meta-analysis of randomized controlled trials
A 2025 protocol for a systematic review and meta-analysis of randomized controlled trials on probiotics for constipation outlines plans to consolidate evidence on microbiota modulation and symptom relief, but the results are not yet available.
Huaier polysaccharides inhibits hepatocellular carcinoma via gut microbiota mediated M2 macrophage polarization
A 2024 animal study found that Huaier polysaccharides (a traditional Chinese medicine) inhibit liver cancer in mice by altering gut microbiota and reducing M2 macrophage polarization, but this has not been tested in humans.
Normal Gut Microbiomes in Diverse Populations: Clinical Implications
A 2024 review highlights that defining a 'normal' microbiome is difficult due to underrepresentation of minority groups and global regions, and calls for population-specific microbiome references to enable customized therapeutics.
Optimal management strategy for patients with infected eczema using whole-genome sequencing: from empiric treatment to personalized systemic antibacterial therapy
A 2025 randomized controlled trial of 60 patients with infected eczema found that personalized antibiotic therapy based on whole-genome sequencing of skin and gut microbiomes led to faster recovery of gut microbial balance compared to standard care.
What defines a healthy gut microbiome?
A 2024 review in Gut argues that the term 'dysbiosis' lacks precision, that defining a 'healthy microbiome' is complicated by individual variability in diet, lifestyle, and environment, and that distinguishing causation from correlation remains a major challenge.
Clinical implications of preterm infant gut microbiome development
A 2021 perspective article on preterm infants notes that early gut microbiome disruptions are linked to later immune and metabolic diseases, but the mechanisms are not fully understood, and most research has focused on full-term babies.